About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | ALTO-300 in Depression (ALTO-300-004)

ALTO-300 in Depression (ALTO-300-004)

NCT05157945·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Alto Neuroscience

Age

18–74

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Have a diagnosis of moderate to severe major depressive disorder
Currently taking a SSRI, SNRI, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks
Must have failed to adequately respond to the current antidepressant medication
Willing to comply with all study assessments and procedures
Must not be pregnant or breastfeeding at time of enrollment or throughout study

You may not be if

Evidence of liver impairment or disease
Active suicidal ideation
Moderate to severe Alcohol Use Disorder
Diagnosed bipolar disorder or psychotic disorder
Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients
Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

The record

StatusCompleted

PhasePhase 2

Taking part148

StartedFeb 2022

UpdatedApr 26, 2024

Conditions

Major Depressive Disorder

Where4

Cerebral - Atlanta
Atlanta, Georgia, United States
Site 171
Jackson, Mississippi, United States
Cerebral - New York City
New York, New York, United States